Project Grant R15DA061114
Award Date
9/30/24
Completion Date
8/31/27
Dollars Obligated
$387K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Boca Raton, FL 33431, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to identify and pharmacologically target novel modulators of the mu-opioid receptor (MOR) signaling pathway. The $772,800 award to the University of Florida will support a 5-year research effort to discover compounds that can dissociate the analgesic and addictive effects of opioids by selectively modifying MOR signaling. The researchers will...
The National Institute on Drug Abuse (NIDA) awarded a $1,213,117 federal Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis to conduct research on developing safer opioid analgesics and antagonists. The project aims to achieve functional selectivity of the mu opioid receptor by activating specific G-protein signaling pathways, with the goal of producing analgesia with fewer side effects like respiratory depression and...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $220,668 to Amalgent Therapeutics, Inc. to develop a novel opioid adjuvant technology. The goal is to create a fixed-dose combination therapeutic that can substantially decrease effective opioid doses while mitigating the abuse potential and other adverse effects of opioid painkillers. The Phase 1 SBIR project will investigate the mechanism...
This federal Project Grant award, valued at $238,276, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding supports research at the University of California, Irvine to investigate the role of the enzyme N-acylethanolamine acid amidase (NAAA) in the development of hyperalgesic priming, a model for studying the transition from acute to chronic pain. The project aims to identify the receptor...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $118,457 to The Trustees of the University of Pennsylvania to conduct research aimed at harnessing the genetics of chronic pain to inform the development of non-addictive analgesic medications. The key objectives of this project are to: 1) characterize the genetic architecture underlying chronic pain liability and addiction; 2) estimate the...
This $13,718,085 Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the clinical development of PF614-MPAR, an opioid analgesic with built-in abuse-deterrent and overdose protection features. The key product being developed is PF614-MPAR, a combination product comprising the TAAP-oxycodone prodrug PF614 and the trypsin inhibitor nafamostat. This novel formulation is designed to provide pain...
This $838,750 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the University of Florida to investigate the role of the GCH1 gene and associated enzyme GTP cyclohydrolase 1 (GTPCH1) in the development and treatment of chronic orofacial neuropathic pain. The researchers hypothesize that inhibiting GTPCH1 via the compound 2,4-diamino-6-hydroxypyrimidine (DAHP) can...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 "Drug Use and Addiction Research Programs," provides $711,875 to the University of Massachusetts Medical School (UMass Medical) to explore the role of the neuropeptide nociceptin in suppressing cocaine reward. The 2-year project from June 2024 to May 2026 will leverage cutting-edge viral and genetic tools to characterize nociceptin signaling in the nucleus accumbens and its...
This National Institute on Drug Abuse (NIDA) Project Grant Award under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $154,568 to The Washington University in St. Louis to investigate the role of enkephalin neurons in the dorsal raphe nucleus on motivational and affective behaviors during chronic pain. The research aims to use dual-color imaging, chemogenetic manipulations, and viral gene editing techniques to determine how these opioid-containing neurons contribute to the...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,510,066 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a planning study for the development of sigma 2 ligands as novel analgesics for chronic neuropathic pain. The funding will support an interdisciplinary research team to: (1) develop an in-silico library of potential sigma 2 ligand analogs, (2) synthesize and evaluate...